Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palbociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 20/20 | 1.00 |
| ▸ | CCND1 known ✓ | P24385 | 16/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 5/20 | 1.00 |
| ▸ | CCND3 | P30281 | 13/20 | 1.00 |
| ▸ | CCND2 | P30279 | 12/20 | 1.00 |
| ▸ | CDK2 | P24941 | 5/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 4/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNT2 | O60583 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palbociclib SCHEMBL29362383 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL30584526 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29379411 | 1.00 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29425547 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL29387795 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL2076416 | 0.99 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Palbociclib SCHEMBL28567292 | 0.98 | CDK4 (0.97) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL30176561 | 0.98 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| SCHEMBL4827183 | 0.98 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CDK2 | |
| Hydrochloric Acid SCHEMBL4828453 | 0.97 | CDK4 (0.98) | CDK4CCND1CCND3CCND2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14771 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144778-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | OLEMA PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081503-A | Application of WWP1 as estrogen receptor positive breast cancer targeting biomarker | — | 2026-05-26 | — | — | CN | claimed |
| CN-122084900-A | Application of CXCL6 in prognosis prediction of small cell lung cancer immunotherapy | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075677-A | GM-CSF loaded tumor cell vaccine and application thereof in preventing and treating liver cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103886-A1 | PHARMACEUTICAL COMPOSITION, KIT AND USE THEREOF | 浙江扬厉医药技术有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-116999565-B | Multiple small nucleic acid delivery system and multiple target vaccine | 四川大学 | 2026-05-19 | — | — | CN | claimed |
| EP-1740184-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | claimed |
| EP-1648889-A1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | Warner-Lambert Company LLC (US) | 2006-04-26 | — | — | EP | claimed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2005094830-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | claimed |
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | PFIZER INC | 2005-03-17 | — | — | US | claimed |
| WO-2005005426-A1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-20 | — | — | WO | claimed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | claimed |